{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-071174","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2024-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.858407+00:00","generated_at":"2026-05-31T08:30:19.710211+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Estrella Immunopharma appoints Hong Zhang as Chairperson and Board member","bullets":["Hong Zhang appointed Chairperson and director effective Aug 14, 2024; board expands from 5 to 6.","Ms. Zhang brings 25+ years financial and corporate strategy experience; previous Chairman Dr. Cheng Liu remains on board.","Compensation: $5,000/quarter as director + $2,500/quarter as Chairperson; expenses reimbursed.","Company also negotiating consulting agreement with entity owned by Ms. Zhang for Asian strategic initiatives; terms pending approval.","Press release notes dosing of first patient in Phase I/II trial STARLIGHT-1 for EB103 in R/R B-cell NHL."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-071174","json":"https://secwatch.observer/filing/0001213900-24-071174.json","markdown":"https://secwatch.observer/filing/0001213900-24-071174.md","text":"https://secwatch.observer/filing/0001213900-24-071174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024071174/0001213900-24-071174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024071174/ea021197101-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:30:19.710211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"017a7ffa11","claim":"Hong Zhang was appointed as Chairperson and a member of the Board of Directors at Estrella Immunopharma, Inc..","evidence_excerpt":"On August 14, 2024, the Board of Directors of Estrella Immunopharma, Inc. (the “Company”) appointed Ms. Hong Zhang as Chairperson and a member of the Company’s Board of Directors (the “Board”), effective as of the same date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024071174/0001213900-24-071174-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairperson and a member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}